TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01523483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo vaginal capsules
Description: Two placebo capsules placed (soy lecithin and sunflower oil) into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
Study: NCT04698525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate Sodium
Description: Comparison between two actives

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine
Study: NCT01364194

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
Study: NCT00386841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10 mg p.o. per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02086331

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast enhanced ultrasound
Description: Infusion of microbubbles to enhance blood vessels in the leg for ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast enhanced ultrasound
Description: Infusion of microbubbles to enhance blood vessels in the leg for ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast enhanced ultrasound
Description: Infusion of microbubbles to enhance blood vessels in the leg for ultrasound

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill test
Description: Exposes you to exercise in a controlled environment. We will see if we can detect this change with our new ultrasound protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill test
Description: Exposes you to exercise in a controlled environment. We will see if we can detect this change with our new ultrasound protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill test
Description: Exposes you to exercise in a controlled environment. We will see if we can detect this change with our new ultrasound protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast enhanced ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast enhanced ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast enhanced ultrasound
Study: NCT03160014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: Drug: SHR3824 20mg/day, oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: Drug: SHR3824 20mg/day, oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: Drug: SHR3824 20mg/day, oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: Drug: SHR3824 20mg/day, oral tablet, single dose
Study: NCT02848937

Intervention type: DEVICE
Intervention: Bath with citrate
Description: bath with citrate which allows the equivalence of mass balance (Ca_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium

Intervention type: DEVICE
Intervention: Bath with citrate and Ca_eq
Description: bath with citrate and Ca_eq of concentrate with 3 mM acetate and 1.5 mM of calcium
Study: NCT02690909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Redy™ Renal Denervation System
Description: Renal Denervation System
Study: NCT03855579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Intraoperative infusion of Levosimendan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Intraoperative infusion of Milrinone
Study: NCT02982408

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High carbohydrate overfeeding
Description: All participant's individual energy requirement will be determined in mega joules (MJ) per day. The energy requirement will be multiplied by a factor 1.5 for a low physical activity level (PAL). The MJ will be rounded up or down to the nearest whole number.~The participant will receive food corresponding to \~25% additional energy above their calculated energy requirement. The 25% extra energy will be supplied to the participants for 4 weeks in the form of food containing simple carbohydrates. The subjects will be given a daily snack package containing processed foods or refined foods such as sweets, cookies, soft drinks, juice etc. To ensure an adequate energy surplus (i.e. weight gain), physical activity has to be decreased to a low level during the 4 weeks overfeeding period.
Study: NCT03329378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 IV, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 8mg/kg IV initial dose, followed by 6mg/kg IV , day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab 840 mg IV initial dose followed by 420 mg IV, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab 840 mg IV initial dose followed by 420 mg IV, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Pegfilgrastim 6mg SC, day 2 Cycled as per arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg every 21 days to complete 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg every 21 days to complete 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m2 IV day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2 IV day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 IV x 1 hour infusion on days 1, 8, and 15
Study: NCT02130414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandimmun® IV
Description: 2 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyCol® capsules
Description: 37.5 mg CyCol® capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyCol® capsules
Description: 37.5 mg CyCol® capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyCol® capsules
Description: 37.5 mg CyCol® capsules
Study: NCT04291144

Intervention type: RADIATION
Intervention: PET-CT using FEOBV
Description: We will inject 300 MBq of 18F-FEOBV in a peripheral vein and scan the internal organs from (0-70 minutes). The patient then rests, and from 180-210min after injection, we will scan the brain on our Siemens High Resolution Research Tomograph.

Intervention type: RADIATION
Intervention: PET-CT using FEOBV
Description: We will inject 300 MBq of 18F-FEOBV in a peripheral vein and scan the internal organs from (0-70 minutes). The patient then rests, and from 180-210min after injection, we will scan the brain on our Siemens High Resolution Research Tomograph.

Intervention type: RADIATION
Intervention: MRI-scan
Description: All patients will have an MRI scan of the brain. T1-weighted images will be used to assess general anatomy and identify white matter. T2-weighted sequences will be performed to quantify competing brain pathology. Also, we will collect functional MRI data.

Intervention type: RADIATION
Intervention: MRI-scan
Description: All patients will have an MRI scan of the brain. T1-weighted images will be used to assess general anatomy and identify white matter. T2-weighted sequences will be performed to quantify competing brain pathology. Also, we will collect functional MRI data.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive assessment
Description: Full neuropsychometric examination including tests in 5 cognitive domains.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive assessment
Description: Full neuropsychometric examination including tests in 5 cognitive domains.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical assessment
Description: Age, sex, duration of disease, patient history and full somatic and neurological examinations. Constipation assessed with Rome-III criteria. Evaluation of Rapid Eye Movement (REM) sleep Behaviour Disorder (RBDSQ) questionnaire. Test for orthostatic hypotension, heart rate variability, and deep breathing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical assessment
Description: Age, sex, duration of disease, patient history and full somatic and neurological examinations. Constipation assessed with Rome-III criteria. Evaluation of Rapid Eye Movement (REM) sleep Behaviour Disorder (RBDSQ) questionnaire. Test for orthostatic hypotension, heart rate variability, and deep breathing.
Study: NCT02119520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin +Atorvastatin

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Platelet rich fibrin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: open flap debridement
Study: NCT01349647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant
Description: Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 9, 20, and 32. Patients will also receive one cycle of chemotherapy with etoposide and cisplatin or carboplatin at week 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant
Description: Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.~Patients will receive vaccine at weeks 1, 2, 3, 4, 8, and 16.
Study: NCT04653519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtually guided minimally invasive preparation
Description: Intraoral virtually guided minimally invasive design with an occlusal reduction of 1.5mm, axial reduction will be performed with 6 degrees axial taper and a circumferential chamfer margin of 0.5mm in width and 0.5mm coronal to the gingival margin. A milled guiding occlusal resin template of the teeth will be checked for fitting then fixed using spot etching and will be used to guide the amount of axial reductions and taper degree.
Study: NCT04088448

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Fluoxetine 20 mg capsule plus Placebo tablet administered once daily after food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Fluoxetine 20 mg capsule plus Metformin 1000 mg extended release tablet administered once daily after food
Study: NCT00806104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides
Description: Dietary supplementation for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrins
Description: Dietary supplementation for 4 weeks
Study: NCT02862691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen/Oxycodone (Oral analgesic)
Description: 2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once
Study: NCT02982408

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High carbohydrate overfeeding
Description: All participant's individual energy requirement will be determined in mega joules (MJ) per day. The energy requirement will be multiplied by a factor 1.5 for a low physical activity level (PAL). The MJ will be rounded up or down to the nearest whole number.~The participant will receive food corresponding to \~25% additional energy above their calculated energy requirement. The 25% extra energy will be supplied to the participants for 4 weeks in the form of food containing simple carbohydrates. The subjects will be given a daily snack package containing processed foods or refined foods such as sweets, cookies, soft drinks, juice etc. To ensure an adequate energy surplus (i.e. weight gain), physical activity has to be decreased to a low level during the 4 weeks overfeeding period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Half of the participants will be randomized to a 3-month exercise-training program.~The training program consists of combined aerobic training and strength training. The training program is performed unsupervised 3 times per week 45 minutes per session for 3 months in the local fitness center. Before engaging in the training program a maximal oxygen consumption test (VO2 max) are conducted and the maximal heartrate (HR) are determined.Participants are wearing the Polar V800 HR monitor and are asked to note their HR in a training log at the end of the last interval at each training session. The strength training program consist of 6 exercises (2 exercises paired together) involving the large muscle groups. The first training session is completed supervised at Rigshospitalet . After 6 weeks the training program is adjusted. Compliance will be ensured by phone calls, text messages and e-mails from study personnel.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Half of the participants will be randomized to a 3-month exercise-training program.~The training program consists of combined aerobic training and strength training. The training program is performed unsupervised 3 times per week 45 minutes per session for 3 months in the local fitness center. Before engaging in the training program a maximal oxygen consumption test (VO2 max) are conducted and the maximal heartrate (HR) are determined.Participants are wearing the Polar V800 HR monitor and are asked to note their HR in a training log at the end of the last interval at each training session. The strength training program consist of 6 exercises (2 exercises paired together) involving the large muscle groups. The first training session is completed supervised at Rigshospitalet . After 6 weeks the training program is adjusted. Compliance will be ensured by phone calls, text messages and e-mails from study personnel.
Study: NCT02862691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine (Injectable local anesthetic)
Description: local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth
Study: NCT02803957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoChord DS1000
Description: Trans-apical, beating heart repair of degenerative mitral valve insufficiency with artificial chordae implanted with the NeoChord DS1000

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Mitral Valve Repair
Description: Surgical repair of degenerative mitral valve insufficiency with cardiopulmonary bypass, and annuloplasty ring and some form of leaflet repair or artificial chordae.
Study: NCT00100048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0518 monotherapy
Description: MK0518 twice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0518 monotherapy
Description: MK0518 twice daily for 10 days
Study: NCT02982408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal physical activity
Description: The other half of the participants will be randomized to a 3-month with normal physical activity level (control).~The participants will have to return to the physical activity level they had before entering the study (baseline level). Compliance will be ensured by phone calls and text messages from study personnel. The subjects will wear a simple pedometer on the hip showing the number of steps. Once a week a text message (SMS-track) is automatically sent asking the participants to enter the weekly number of steps. The test personnel receive the reply and contact the participant if the number of steps does not match the baseline level. During the first and the last 7 days of the exercise intervention participants are wearing 2 accelerometers measuring their physical activity behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal physical activity
Description: The other half of the participants will be randomized to a 3-month with normal physical activity level (control).~The participants will have to return to the physical activity level they had before entering the study (baseline level). Compliance will be ensured by phone calls and text messages from study personnel. The subjects will wear a simple pedometer on the hip showing the number of steps. Once a week a text message (SMS-track) is automatically sent asking the participants to enter the weekly number of steps. The test personnel receive the reply and contact the participant if the number of steps does not match the baseline level. During the first and the last 7 days of the exercise intervention participants are wearing 2 accelerometers measuring their physical activity behavior.
Study: NCT02468258

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial flushing
Description: Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected and centrifuged at 600 rpm for 10 min and 5-ml sample of supernatant was obtained for ELISA estimation of tumor necrosis factor-α (TNF-α), granulocyte colony-stimulating factor (G-CSF), leptin and anti-Mullerian Hormone (AMH) levels in both groups. The remaining amount was used for endometrial flushing
Study: NCT04128826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Using the cable machine, shoulders will be flexed to 180° for both (PROM \& FROM) groups throughout the training; FROM would train with full elbow extension (complete elbow flexion to extension) whereas PROM will train with partial elbow extension from 60° to 110°. A total of 8 sessions, 2 sessions/week for 4 weeks will be carried out by both groups. CON group will not participate in training protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Using the cable machine, shoulders will be flexed to 180° for both (PROM \& FROM) groups throughout the training; FROM would train with full elbow extension (complete elbow flexion to extension) whereas PROM will train with partial elbow extension from 60° to 110°. A total of 8 sessions, 2 sessions/week for 4 weeks will be carried out by both groups. CON group will not participate in training protocol.
Study: NCT00431600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% Oxygen
Description: 100% Oxygen- breathing over 30 minutes
Study: NCT02533479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: three alternate days weekly along 4 weeks.
Study: NCT01115465

Intervention type: DEVICE
Group type: OTHER
Intervention: Macroplastique
Description: Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) primarily due to intrinsic sphincter deficiency (ISD).
Study: NCT00100048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0518 monotherapy
Description: MK0518 twice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0518 monotherapy
Description: MK0518 twice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0518 combination therapy
Description: MK0518 twice daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0518 combination therapy
Description: MK0518 twice daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0518 combination therapy
Description: MK0518 twice daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0518 combination therapy
Description: MK0518 twice daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: efavirenz
Description: efavirenz 600 mg every night at bedtime for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: tenofovir
Description: tenofovir 300 mg daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: tenofovir
Description: tenofovir 300 mg daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: tenofovir
Description: tenofovir 300 mg daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: tenofovir
Description: tenofovir 300 mg daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: tenofovir
Description: tenofovir 300 mg daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: lamivudine
Description: lamivudine 300 mg daily for 48 weeks
Study: NCT04089592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intravenous dexmedetomidine 0.6mcg/kg in 100ml normal saline 0.9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: intravenous fentanyl at 2mcg/kg in 100ml saline
Study: NCT00100048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: lamivudine
Description: lamivudine 300 mg daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: lamivudine
Description: lamivudine 300 mg daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: lamivudine
Description: lamivudine 300 mg daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: lamivudine
Description: lamivudine 300 mg daily for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo monotherapy
Description: Placebo to MK0518 twice daily
Study: NCT04123821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway
Description: A disposable nasopharyngeal airway of appropriate size will be selected for patients allocated to the intervention group with 5L/min oxygen through nasal cannula